A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Omeprazole in Healthy Male and Female Adults.

Trial Profile

A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Omeprazole in Healthy Male and Female Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2012

At a glance

  • Drugs Sucroferric oxyhydroxide (Primary) ; Omeprazole
  • Indications Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Helicobacter infections; Hyperphosphataemia; Peptic ulcer; Zollinger-Ellison syndrome
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 Dec 2011 Actual patient number (45) added as reported by ClinicalTrials.gov.
    • 09 Dec 2011 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 09 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top